这是近日第三宗并购交易。此笔交易将缔造一家年营业额超过33亿欧元的制药企业，同时将增加UCB开发末期产品的数量。

The deal, the third of its kind in almost as many days, will create a company with annual turnover of more than .3bn and increase the number of late-stage products at UCB.

UCB, the Belgian drug maker, was yesterday the latest company to join in the rash of mergers among Europe’s medium-sized pharmaceutical groups, with an agreed .4bn ($5.6bn) cash and share offer for Schwarz Pharma.

比利时制药商UCB昨日与Schwarz Pharma达成协议，以44亿欧元（合56亿美元）现金加股票的出价收购后者，令UCB成为最新一家加入欧洲中型制药集团并购浪潮的企业。